Update on Clinical Development Study
The Clinical Development Study with the Sencell sensor will continue for a few more weeks.
– We operate complex and pioneering sensor technology and strive to ensure high quality at all stages of the process. We therefore want to extend the Clinical Development Study by a few weeks more than previously communicated, says CEO Joacim Holter.
The sensors we use in the study are handmade in our laboratory in Reutlingen, Germany. This is of course time-consuming work, due to the small size of the sensors and our quality focus. In the future, the sensors will of course be mechanically produced in a streamlined manner.
In February, Lifecare announced that sensors used in a three-day clinical study continue to work in an in vitro set up. This confirms the expectation of a sensor longevity that far exceeds the lifetime of existing and commercially available needle sensors for glucose monitoring. The company reported that sensors used in a three-day clinical study continue to work in an in vitro set up, showing an operational longevity for a total of 4 weeks and are still ongoing.